Symphogen A/S To Report Preliminary Safety And Exploratory Efficacy Data From A Phase 1 Study Of Sym004, Anti-EGFR Monoclonal Antibody Mixture At American Society of Clinical Oncology
5/29/2014 7:27:03 AM
Symphogen A/S, a private biopharmaceutical company with leadership in recombinant antibody mixtures for therapeutic use, today reported preliminary safety and exploratory efficacy data from a Phase 1 clinical study of Sym004, an investigational anti-EGFR monoclonal antibody mixture, administered biweekly, that will be presented in a poster at the upcoming American Society for Clinical Oncology (ASCO) Annual Meeting being held May 30 – June 3, 2014 in Chicago, IL.
Help employers find you! Check out all the jobs and post your resume.
comments powered by